Transcriptional targets of senataxin and E2 promoter binding factors are associated with neuro-degenerative pathways during increased autophagic flux |
|
Author: | Casey, Aaron E.1,2; Liu, Wenjun3; Hein, Leanne K.4; |
Organizations: |
1Computational and Systems Biology Program, Precision Medicine Theme, South Australian Health and Medical Research Institute, North Terrace, Adelaide, SA, 5000, Australia 2Australian Centre for Precision Health, Cancer Research Institute, University of South Australia, Adelaide, Australia 3Dame Roma Mitchell Cancer Research Laboratories, Adelaide Medical School, Faculty of Health and Medical Sciences, University of Adelaide, Adelaide, Australia
4Lysosomal Health in Ageing, Hopwood Centre for Neurobiology, Lifelong Health Theme, South Australian Health and Medical Research Institute, Adelaide, Australia
5Computational Medicine, Faculty of Medicine, University of Oulu, Oulu, Finland 6Center for Life Course Health Research, Faculty of Medicine, University of Oulu, Oulu, Finland |
Format: | article |
Version: | published version |
Access: | open |
Online Access: | PDF Full Text (PDF, 1.4 MB) |
Persistent link: | http://urn.fi/urn:nbn:fi-fe2023060752721 |
Language: | English |
Published: |
Springer Nature,
2022
|
Publish Date: | 2023-06-07 |
Description: |
AbstractAutophagy is an intracellular recycling process that degrades harmful molecules and enables survival during starvation, with implications for diseases including dementia, cancer and atherosclerosis. Previous studies demonstrate how a limited number of transcription factors (TFs) can increase autophagy. However, this knowledge has not resulted in translation into therapy, thus, to gain understanding of more suitable targets, we utilized a systems biology approach. We induced autophagy by amino acid starvation and mTOR inhibition in HeLa, HEK 293 and SH-SY5Y cells and measured temporal gene expression using RNA-seq. We observed 456 differentially expressed genes due to starvation and 285 genes due to mTOR inhibition (PFDR < 0.05 in every cell line). Pathway analyses implicated Alzheimer’s and Parkinson’s diseases (PFDR ≤ 0.024 in SH-SY5Y and HeLa) and amyotrophic lateral sclerosis (ALS, PFDR < 0.05 in mTOR inhibition experiments). Differential expression of the Senataxin (SETX) target gene set was predicted to activate multiple neurodegenerative pathways (PFDR ≤ 0.04). In the SH-SY5Y cells of neuronal origin, the E2F transcription family was predicted to activate Alzheimer’s disease pathway (PFDR ≤ 0.0065). These exploratory analyses suggest that SETX and E2F may mediate transcriptional regulation of autophagy and further investigations into their possible role in neuro-degeneration are warranted. see all
|
Series: |
Scientific reports |
ISSN: | 2045-2322 |
ISSN-E: | 2045-2322 |
ISSN-L: | 2045-2322 |
Volume: | 12 |
Issue: | 1 |
Article number: | 17665 |
DOI: | 10.1038/s41598-022-21617-2 |
OADOI: | https://oadoi.org/10.1038/s41598-022-21617-2 |
Type of Publication: |
A1 Journal article – refereed |
Field of Science: |
3111 Biomedicine 1182 Biochemistry, cell and molecular biology |
Subjects: | |
Funding: |
This article was funded by South Australian Health and Medical Research Institute. |
Copyright information: |
© The Author(s) 2022. This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. |
https://creativecommons.org/licenses/by/4.0/ |